Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Cancer|February 29, 2012
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsEun-Jung Jung, Libero Santarpia, Juyeon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2017
Recurrence dynamics of breast cancer according to baseline body mass indexElia Biganzoli, Christine Desmedt, Marco Fornili, et al.
Journal of the National Cancer Institute|December 10, 2013
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trialAngelo Di Leo, Guy Jerusalem, Lubos Petruzelka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast CancerChee Khoon Lee, Lucy Davies, Val J Gebski, et al.
Breast Cancer Research and Treatment|February 5, 2013
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodologySally Anne Garnett, Miguel Martin, Guy Jerusalem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Therapeutic Advances in Medical Oncology|December 20, 2019
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)Emanuela Risi, Chiara Biagioni, Matteo Benelli, et al.
NPJ Breast Cancer|May 29, 2021
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancerTamar Zahavi, Mali Salmon-Divon, Roberto Salgado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerAngelo Di Leo, Guy Jerusalem, Lubos Petruzelka, et al.
Pageof 18